Veterinary Stereotactic Radiosurgery Systems

Global Veterinary Stereotactic Radiosurgery Systems Market to Reach US$5.3 Billion by 2030

The global market for Veterinary Stereotactic Radiosurgery Systems estimated at US$3.1 Billion in the year 2024, is expected to reach US$5.3 Billion by 2030, growing at a CAGR of 9.4% over the analysis period 2024-2030. Gamma Knife, one of the segments analyzed in the report, is expected to record a 11.6% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the LINAC segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$840.5 Million While China is Forecast to Grow at 13.3% CAGR

The Veterinary Stereotactic Radiosurgery Systems market in the U.S. is estimated at US$840.5 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 13.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.5% and 8.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

Global Veterinary Stereotactic Radiosurgery System Market – Key Trends & Drivers Summarized

Why Is Stereotactic Radiosurgery Revolutionizing Veterinary Oncology?

Stereotactic radiosurgery (SRS) has emerged as a groundbreaking treatment option in veterinary oncology, offering a highly precise, non-invasive alternative to conventional surgery and radiation therapy. This advanced technique utilizes focused radiation beams to target tumors with pinpoint accuracy, minimizing damage to surrounding healthy tissues while effectively destroying cancerous cells. Veterinary SRS is particularly beneficial for treating brain tumors, nasal tumors, and osteosarcomas, where traditional surgical options are either too invasive or pose significant risks. The ability of SRS to deliver high-dose radiation in a single or limited number of sessions significantly reduces treatment times, making it a more convenient option for both veterinarians and pet owners. Additionally, SRS is being explored for non-oncological applications, such as treating neurological disorders and pain management in animals with inoperable spinal conditions. With the rising incidence of cancer in companion animals, driven by increasing pet longevity and improved diagnostic capabilities, stereotactic radiosurgery is becoming an essential tool in advanced veterinary care, offering new hope for pets diagnosed with previously untreatable conditions.

What Are the Technological Advancements Driving Veterinary Stereotactic Radiosurgery?

The field of veterinary SRS has seen remarkable technological advancements, improving treatment precision, safety, and accessibility. One of the most significant developments is the integration of real-time image-guided radiation therapy (IGRT), which allows veterinarians to continuously track tumor position during treatment, ensuring optimal accuracy. The use of high-resolution computed tomography (CT) and magnetic resonance imaging (MRI) for treatment planning has further enhanced the precision of SRS, enabling highly targeted radiation delivery with minimal collateral damage. The adoption of robotic radiosurgery platforms, such as CyberKnife, has revolutionized veterinary oncology by providing automated, real-time adjustments to compensate for patient movement during treatment. Additionally, advancements in radiation dose modulation and intensity-modulated radiosurgery (IMRS) have improved treatment effectiveness while reducing side effects. The increasing availability of dedicated veterinary radiation oncology centers equipped with cutting-edge SRS systems is also expanding access to this life-saving treatment. As these technologies continue to evolve, veterinary stereotactic radiosurgery is becoming an increasingly viable option for treating complex tumors and neurological disorders in animals.

What Challenges Are Limiting the Expansion of Veterinary Stereotactic Radiosurgery?

Despite its transformative potential, the adoption of veterinary SRS faces several significant challenges. One of the biggest barriers is the high cost of acquiring and maintaining SRS systems, making this treatment option accessible primarily in well-funded specialty hospitals and academic institutions. The complex nature of SRS also requires highly trained radiation oncologists and physicists, leading to a shortage of qualified veterinary professionals capable of performing these procedures. Additionally, while SRS provides a non-invasive alternative to conventional surgery, some tumors may still require adjunct therapies, such as chemotherapy or immunotherapy, increasing overall treatment costs for pet owners. Limited insurance coverage for advanced radiation therapy in veterinary medicine further restricts access to SRS, as many pet owners struggle to afford the high costs associated with precision oncology treatments. Another challenge is the need for continued research into the long-term effects of stereotactic radiosurgery in veterinary patients, as data on survival rates and post-treatment quality of life remains limited compared to human oncology studies. Overcoming these challenges will require increased investment in veterinary radiation oncology training, broader insurance coverage, and ongoing research into optimizing SRS treatment protocols for different animal species.

What Are the Key Growth Drivers of the Veterinary Stereotactic Radiosurgery Market?

The growth in the veterinary stereotactic radiosurgery system market is driven by several factors, including rising cancer rates in pets, advancements in radiation therapy technology, and increasing investment in veterinary specialty care. The growing prevalence of oncology-focused veterinary hospitals has expanded access to SRS, making it a viable treatment option for more pet owners. Technological innovations in robotic radiosurgery, real-time imaging, and automated treatment planning have further improved the safety and efficacy of SRS procedures. Additionally, the increasing willingness of pet owners to pursue advanced cancer treatments, coupled with the expanding availability of pet insurance coverage for radiation therapy, is fueling market growth. As veterinary oncology continues to evolve, the demand for precise, non-invasive cancer treatments will drive further adoption of stereotactic radiosurgery, solidifying its role as a cornerstone of modern veterinary medicine.

SCOPE OF STUDY:

The report analyzes the Veterinary Stereotactic Radiosurgery Systems market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Gamma Knife, LINAC, Proton Beam Radiation Therapy / Flash-RT, CyberKnife); End-Use (Hospitals & Clinics, Academic & Research Institutions)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Accuray Incorporated
• ALCEN
• Arthrex Vet Systems
• C.R. Bard Inc.
• CIVCO Radiotherapy
• Elekta AB
• Ion Beam Applications SA
• Medtronic
• Nanovi Radiotherapy A/S
• PetCure Oncology
• ProBeam
• RaySearch Laboratories
• Stereotactic Radiosurgery Systems
• Varian Medical Systems, Inc.
• ViewRay
• Xcision Medical Systems
• Xstrahl
• VetCure Oncology
• GammaVet
• RadVet

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.